About Jeito

The firm’s first fund dedicated to biopharmaceuticals.

Jeito Capital is a leading global investment company. Jeito was founded and directed by Dr. Rafaèle Tordjman, a hematologist and former fellow in Paris University Hospitals and research scientist at INSERM, who has been an investor in life sciences for more than 20 years.

Jeito I has raised 534 million euros (630 million dollars) in September 2021

Jeito Capital has developed an approach focused on patient benefits, financing and accelerating cutting-edge medical innovation. Jeito supports and accompanies entrepreneurs through its multidisciplinary team of experts across the entire drug value chain, as well as through a significant capital contribution to ensure the growth of companies. Jeito thus contributes to the emergence of leaders in specific therapeutic areas and accelerates the commercialization of innovative treatments throughout the world, particularly in Europe and the United States, for the benefit of patients.

Jeito Capital has built a solid and diverse portfolio of European Biopharma companies. Jeito has invested in diversified therapeutic areas such as immuno-oncology, ophthalmology, rare skeletal diseases, severe respiratory diseases, fibrosis and associated cancers.


Our team

Jeito benefits from a multi-talented, integrated team with over 20 years’ experience across the entire value chain of the healthcare sector, from developing groundbreaking therapies to mastering IP strategy, achieving regulatory milestones and bringing them to market.

Our approach

Jeito Capital has a unique, investment strategy, providing significant capital and support in continuity to entrepreneurs and companies from clinical development to market access for breakthrough innovations.

Our mission

Go faster for the patient,
Further with the entrepreneur

In teams

Discover Jeito members

A multidisciplinary and multi-talented team of healthcare professionals, experienced in the entire value chain of therapeutic innovation development.